Seulki Lee, PhD
Interim CEO
Dr. Lee, founder, is an expert in drug and protein delivery. His research is focused on identifying novel targets critically involved in the origination of the disease. He discovered NLY01 and, in collaboration with Dr. T. Dawson, at John’s Hopkins School of Medicine, proved its exceptional neuroprotective activity in animal models of Parkinson’s disease, which led to founding of Neuraly.
Viktor Roschke, PhD
CSO, Head R&D
Dr. Roschke, co-founder, is Chief Scientific Officer and Head of Research of and Development. He has more than 20 years of experience in drug development as senior executive in biotech companies such as Human Genome Sciences, Cogenesys, Teva Pharmaceuticals.
Zoltan Mari, MD
Dr. Zoltan Mary is co-founder & Interim Chief Medical Officer. He is a world recognized physician specializing in movement disorders. Dr. Z. Mary is also critically involved in clinical research as an investigator in multiple clinical trials for Parkinson Disease.
Adam Bell, PhD, RAC
Vice President, Clinical and Regulatory Affairs
Dr. Adam Bell is Vice-President of Clinical and Regulatory Affairs. He brings more than 15 years of experience as an inventor and leader in the biotech and pharma industries.  Having managed full development programs from pre-clinical through pivotal clinical trials, he brings a breadth of experience with FDA compliant pharm/tox, manufacturing, and clinical development.
Hanseok Ko, PhD
Head of Pre-clinical Research
Dr. Ko’s is an internationally acclaimed scientist who’s research is focused on understanding the mechanisms underlying the neurodegeneration in Parkinson’s disease (PD). His work elucidated new mechanisms of how PD-related genes contribute to pathogenesis of PD, which led to unique and novel therapeutic approaches to treat this devastating disease.